Cargando…

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer

OBJECTIVE: HER2 status in breast cancer is an essential parameter in individual therapeutic decision-making and is routinely assessed in primary tumors in accordance with international recommendations. Reports of HER2 heterogeneity raise the question of basing treatment decisions on HER2 status in m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellas, Ulrika, Bauer, Annette, Baroš, Ilija Vladimir, Fattorini, Caterina, Tot, Tibor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362429/ https://www.ncbi.nlm.nih.gov/pubmed/37483511 http://dx.doi.org/10.3389/fonc.2023.1167567

Ejemplares similares

Intertumor heterogeneity in vascularity and invasiveness of artificial melanoma brain metastases
por: Simonsen, Trude G., et al.
Publicado: (2015)

Intratumor and Intertumor Heterogeneity in Melanoma
por: Grzywa, Tomasz M., et al.
Publicado: (2017)

The significance of intertumor and intratumor heterogeneity in liver cancer
por: Liu, Jinping, et al.
Publicado: (2018)

Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers
por: Kuncman, Wojciech, et al.
Publicado: (2021)

Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations
por: Lu, Kevin, et al.
Publicado: (2022)

Integrative meta-analysis of gene expression profiles identifies FEN1 and ENDOU as potential diagnostic biomarkers for cervical squamous cell carcinoma
por: Basic, Vladimir, et al.
Publicado: (2021)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing
por: Lin, Weitao, et al.
Publicado: (2021)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis
por: Bergmann, Natalie, et al.
Publicado: (2020)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
por: Skaga, Erlend, et al.
Publicado: (2019)

Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity
por: Mejbel, Haider A., et al.
Publicado: (2019)

Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases
por: Woldmar, N., et al.
Publicado: (2022)

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2018)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma
por: Tan, Daniel J., et al.
Publicado: (2020)

Primary Sclerosing Cholangitis–Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity
por: Kamp, Eline J.C.A., et al.
Publicado: (2021)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012)

Prognostic implications of HER2 heterogeneity in gastric cancer
por: Motoshima, Shigenobu, et al.
Publicado: (2018)

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
por: Chen, Runzhe, et al.
Publicado: (2022)

EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radiotherapy
por: Shen, Li, et al.
Publicado: (2008)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

How we treat HER2-positive brain metastases
por: Stavrou, E., et al.
Publicado: (2021)

74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
por: Hulsbergen, Alexander, et al.
Publicado: (2020)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole
por: Dhani, N C, et al.
Publicado: (2015)

Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity
por: Campbell, Katie M., et al.
Publicado: (2018)

Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1
por: Selberherr, Andreas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bkdleumu41l55lsomdkahin8t0